Conclusions
nausea, HPV-related anogenital disease
HSIL
Intra-anal artesunate is a safe and well-tolerated treatment for anal HSIL and may be a promising addition in the therapeutic armamentarium against HPV-related anogenital disease. It is easily self-administered in the suppository form. Due to the frequent nausea that patients experienced at the 600-mg dose, the placebo-controlled, randomized Phase 2B trial will utilize the 400-mg suppository. We would like to thank Dr. Namandje Bumpus and Dr. Craig Hendrix in the Division of Clinical Pharmacology with the Department of Internal Medicine for their contributions to the study design.